Building upon the background above and our research achievements, we tested the effect of intranasal treatment with a new nanoformulation containing melatonin, insulin, and THC on AD-related cognitive impairment and pathologic changes using an AD mouse model. The gene discussed is INS; the disease is Alzheimer disease.